{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:22:49Z","timestamp":1760710969971},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reliable serological assays are needed to understand the real impact of COVID-19. In order to compare the efficiency of different COVID-19 vaccines used in the National Vaccination Program in Tunisia, we have developed a quantitative in-house ELISA. The ELISA is based on the ectodomain of the SARS-CoV-2 Spike Baculovirus recombinant protein. We used a panel of 145 COVID-19 RT-PCR positive serum samples and 116 pre-pandemic serum samples as a negative panel. The validation was carried out by comparison to four commercial techniques (Vidas SARS-CoV-2 IgG anti-RBD Biom\u00e9rieux, Elecsys Anti-Nucleocapsid of SARS-CoV-2 Roche, cPass GenScript and the quantitative Elecsys Anti-RBD of SARS-CoV-2, Roche). For the evaluation of the National Vaccination campaign, we have included 115 recipients who received one of the approved vaccines. The qualitative performances of the developed ELISA gave 96% sensitivity, 97.5% specificity and 0.968 accuracy. For the evaluation of the different brand of vaccines in recipients not previously infected with SARS-CoV-2, it seems that mRNA vaccine of Pfizer\/BioNTech has shown a higher efficacy compared to inactivated virus vaccines. COVID-19 convalescent individuals have generated poor antibody responses. Nevertheless, when they are vaccinated with any brand of the COVID-19 vaccines, many of them mounted an exponential increase of the induced immune responses, qualified as a \u201chybrid vigor immunity\u201d. Our developed in-house ELISA seems to be very efficient in evaluating the effectiveness of anti-COVID-19 vaccination. Platforms based on mRNA vaccine are better performing than those based on inactivated virus.<\/jats:p>","DOI":"10.1038\/s41598-022-15378-1","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T16:03:30Z","timestamp":1656950610000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans"],"prefix":"10.1038","volume":"12","author":[{"given":"Mariem","family":"Gdoura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Ben","family":"Ghaloum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriem Ben","family":"Hamida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa","family":"Chamsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henda","family":"Triki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chokri","family":"Bahloul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"15378_CR1","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID19-March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"key":"15378_CR2","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/."},{"key":"15378_CR3","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-12-2","author":"RM Burgos","year":"2021","unstructured":"Burgos, R. M. et al. The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution. Drugs Context. https:\/\/doi.org\/10.7573\/dic.2020-12-2 (2021).","journal-title":"Drugs Context."},{"key":"15378_CR4","unstructured":"WHO: COVID-19 vaccine tracker and landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"15378_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108162","author":"P Ghasemiyeh","year":"2021","unstructured":"Ghasemiyeh, P., Mohammadi-Samani, S., Firouzabadi, N., Dehshahri, A. & Vazin, A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int. Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2021.108162 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"15378_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02383-z","author":"A Maxmen","year":"2021","unstructured":"Maxmen, A. The fight to manufacture COVID vaccines in lower-income countries. Nature https:\/\/doi.org\/10.1038\/d41586-021-02383-z (2021).","journal-title":"Nature"},{"key":"15378_CR7","unstructured":"WHO: https:\/\/covid19.who.int\/region\/emro\/country\/tn."},{"key":"15378_CR8","unstructured":"Evax: https:\/\/www.evax.tn\/."},{"key":"15378_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103916","author":"N Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2103916 (2021).","journal-title":"N. Engl. J. Med."},{"key":"15378_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature https:\/\/doi.org\/10.1038\/s41586-020-03041-6 (2021).","journal-title":"Nature"},{"key":"15378_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.08.023","author":"J Douxfils","year":"2021","unstructured":"Douxfils, J., Gillot, C., Mullier, F. & Favresse, J. Post-SARS-CoV-2 vaccination specific antibody decrease\u2014Thresholds for determining seroprevalence and seroneutralization differ. J. Infect. https:\/\/doi.org\/10.1016\/j.jinf.2021.08.023 (2021).","journal-title":"J. Infect."},{"key":"15378_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.09.013","author":"C Dimeglio","year":"2021","unstructured":"Dimeglio, C., Herin, F., Martin-Blondel, G., Miedoug\u00e9, M. & Izopet, J. Antibody titers and protection against a SARS-CoV-2 infection. J. Infect. https:\/\/doi.org\/10.1016\/j.jinf.2021.09.013 (2021).","journal-title":"J. Infect."},{"key":"15378_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nature06536","author":"KE Jones","year":"2008","unstructured":"Jones, K. E. et al. Global trends in emerging infectious diseases. Nature https:\/\/doi.org\/10.1038\/nature06536 (2008).","journal-title":"Nature"},{"key":"15378_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00266-4","author":"I Knezevic","year":"2021","unstructured":"Knezevic, I. et al. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community. Lancet Microbe https:\/\/doi.org\/10.1016\/S2666-5247(21)00266-4 (2021).","journal-title":"Lancet Microbe"},{"key":"15378_CR15","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00501.5","author":"LJ Carter","year":"2020","unstructured":"Carter, L. J. et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent. Sci. https:\/\/doi.org\/10.1021\/acscentsci.0c00501.5 (2020).","journal-title":"ACS Cent. Sci."},{"key":"15378_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"15378_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9100803","author":"TA Alandijany","year":"2020","unstructured":"Alandijany, T. A. et al. Development and optimization of in-house ELISA for detection of human IgG antibody to SARS-CoV-2 full length spike protein. Pathogens https:\/\/doi.org\/10.3390\/pathogens9100803 (2020).","journal-title":"Pathogens"},{"key":"15378_CR18","unstructured":"JORF n\u00b00293 du 4 d\u00e9cembre 2020Texte n\u00b0 55. https:\/\/www.legifrance.gouv.fr\/eli\/arrete\/2020\/12\/3\/SSAZ2033724A\/jo\/texte."},{"key":"15378_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115140","author":"F Wolffa","year":"2020","unstructured":"Wolffa, F. et al. Monitoring antibody response following SARS-CoV-2 infection: Diagnostic efficiency of 4 automated immunoassays. Diagn. Microbiol. Infect. Dis. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115140 (2020).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"15378_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2021.e00222","author":"Z Szab\u00f3","year":"2021","unstructured":"Szab\u00f3, Z. et al. Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors. Pract. Lab. Med. https:\/\/doi.org\/10.1016\/j.plabm.2021.e00222 (2021).","journal-title":"Pract. Lab. Med."},{"key":"15378_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3103","author":"L Grzelak","year":"2020","unstructured":"Grzelak, L. et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abc3103 (2020).","journal-title":"Sci. Transl. Med."},{"key":"15378_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2029466","author":"L Julie","year":"2021","unstructured":"Julie, L., Gerberding, M. D., Barton, F. & Haynes, M. D. Vaccine innovations past and future. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMp2029466 (2021).","journal-title":"N. Engl. J. Med."},{"key":"15378_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00915-3","author":"Q Liu","year":"2021","unstructured":"Liu, Q., Qin, C., Liu, M. & Liu, J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis. Infect. Dis. Poverty https:\/\/doi.org\/10.1186\/s40249-021-00915-3 (2021).","journal-title":"Infect. Dis. Poverty"},{"key":"15378_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2481","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: Antibody levels fall after second Pfizer dose, but protection against severe disease remains, studies indicate. BMJ https:\/\/doi.org\/10.1136\/bmj.n2481 (2021).","journal-title":"BMJ"},{"key":"15378_CR25","doi-asserted-by":"crossref","unstructured":"Nanduri, S., et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant\u2014National Healthcare Safety Network, March 1\u2013August 1, 2021. CDC Weekly\/August 27, 2021\/70 (34); 1163\u20131166. https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7034e3.htm.","DOI":"10.15585\/mmwr.mm7034e3"},{"key":"15378_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02796-w","author":"S Mallapaty","year":"2021","unstructured":"Mallapaty, S. China\u2019s COVID vaccines have been crucial\u2014Now immunity is waning. Nature https:\/\/doi.org\/10.1038\/d41586-021-02796-w (2021).","journal-title":"Nature"},{"key":"15378_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj2258","author":"C Crotty","year":"2021","unstructured":"Crotty, C. Hybrid immunity. Science https:\/\/doi.org\/10.1126\/science.abj2258 (2021).","journal-title":"Science"},{"key":"15378_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02795-x","author":"E Callaway","year":"2021","unstructured":"Callaway, E. COVID super-immunity: One of the pandemic\u2019s great puzzles. Nature https:\/\/doi.org\/10.1038\/d41586-021-02795-x (2021).","journal-title":"Nature"},{"key":"15378_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03696-9","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature https:\/\/doi.org\/10.1038\/s41586-021-03696-9 (2021).","journal-title":"Nature"},{"key":"15378_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04060-7","author":"A Cho","year":"2021","unstructured":"Cho, A. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature https:\/\/doi.org\/10.1038\/s41586-021-04060-7 (2021).","journal-title":"Nature"},{"key":"15378_CR31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026116","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2026116 (2020).","journal-title":"N. Engl. J. Med."},{"key":"15378_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe0240","author":"K Roltgen","year":"2020","unstructured":"Roltgen, K. et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abe0240 (2020).","journal-title":"Sci. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15378-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:11:50Z","timestamp":1669356710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15378"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15378-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11298"}}